Standard AAV Packaging
Cyagen offers high-purity, high-titer AAV vectors for gene therapy and in vivo research. Our optimized three-plasmid system ensures high infection efficiency, low endotoxin levels, and broad serotype compatibility.
High Purity & Titer
Achieves robust gene expression in dividing and non-dividing cells.
Broad Serotype Selection
Offers multiple serotypes for different tissues and applications.
Fast & Reliable Delivery
Standard AAV projects ship in as fast as 2 weeks with rigorous QC testing.
Overview
Workflow
FAQs
Custom AAV Packing Services
To ensure the reliability of viral packaging, we maintain strict control over viral titer, purity, and
functional activity. Our AAV production employs a three-plasmid co-transfection system with multiple
serotype
options. Each batch achieves >95% purity with endotoxin levels <10 EU/mL. We further guarantee viral
quality
and
performance through in-house validation, where our technical team evaluates infectivity, specificity, and
transduction efficiency in both cultured cells and mouse models. This comprehensive workflow provides strong
assurance of AAV quality and experimental consistency.
| Service Type | Group | Titer | Turnaround Time |
|---|---|---|---|
| Plasmid Construction | Gene synthesis required | \ | 2-4 weeks |
| No gene synthesis required | \ | 1-3weeks | |
| AAV Packing | 1×1012 vg | ≥5×1012 vg/ml | As fast as 2 weeks |
| 5×1012 vg | ≥1×1013 vg/ml | ||
| 1×1013 vg | ≥1×1013 vg/ml | ||
| 2×1013 vg | ≥1×1013 vg/ml | ||
| 5×1013 vg | ≥1×1013 vg/ml | ||
| 1×1014 vg | ≥1×1013 vg/ml | ||
| others | others |
Data Validation Highlights:
Figure 1. Schematic Diagram of AAV Vector Quality Control Results
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Contact Us
Connect with our experts for your viral vector packaging needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.